By NOAM N. LEVEY and JENNIFER HABERKORN In a much-anticipated piece of political theater, seven leading pharmaceutical executives appeared before a powerful Senate committee Tuesday for a grilling from lawmakers who pledged a historic bipartisan effort to rein in skyrocketing prescription drug prices. But even as drug prices have emerged as one of the few areas of common […]
Here, you will find all mentions of NCHC in the news from 2017-present. Please see here for all 2016 and previous media mentions.
WSJ: Would Drug Price Controls Kill Innovation?
The original letter to the editor was published on January 15, 2018 and can be found here. The article in which the letter responds to can be found here. By John Rother The U.S. is alone among developed nations in failing to assure more affordable medications for its citizens. Medicare trustees have an obligation to act prudently to obtain fair prices for beneficiaries. Recent research has […]
Op-Ed: The Necessity Of Exploiting Pricing Power in a Post-Consolidated Health Care World
By John Rother & David Introcaso Originally posted on Morning Consult. You can read the original op-ed here. Americans are forced to spend over $1 trillion annually on health care services that do not improve their health. What causes this is not the amount of health care services we consume. Compared to similar countries, the […]
POLITICO: Why Trump still needs Obamacare
By SARAH KARLIN-SMITH, RACHEL ROUBEIN and BRIANNA EHLEY A Texas judge’s stunning declaration that Obamacare is unconstitutional not only kneecaps the health care law, it would also cripple President Donald Trump’s entire health care agenda. Trump wants lower drug prices, drastic action on the opioid crisis and protection for people with pre-existing conditions. Those are […]
Op-Ed: With a New Congress, a Window Opens to Finally Bring Down Drug Prices
You can read the original op-ed published in STAT News here. With the new Congress mostly in place, now split between a Democratic House and a Republican Senate, a new dynamic is in place. Any legislation, including efforts to rein in drug prices, will need to have bipartisan support to move forward. Bringing pricing restraint […]
- 1
- 2
- 3
- 4
- Next Page »